Back to Search
ROBERT ORLOWSKI, MD
MD
Hematology & Oncology Physician
NPI: 1417276379Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
MD446468(PA)
Research & Publications (20)
Proteasome inhibitors in cancer therapy: lessons from the first decade.
PMID 18347166·Clin Cancer Res·2008
6-review
Altered editing in cyclic nucleotide phosphodiesterase 8A1 gene transcripts of systemic lupus erythematosus T lymphocytes.
PMID 18462347·Immunology·2008
8-other
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
PMID 17679727·J Clin Oncol·2007
3-trial
Targeting the proteasome as a therapeutic strategy against haematological malignancies.
PMID 16433592·Expert Opin Investig Drugs·2006
6-review
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
PMID 15626743·Blood·2005
3-trial
The ubiquitin proteasome pathway from bench to bedside.
PMID 16304384·Hematology Am Soc Hematol Educ Program·2005
8-other
The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer.
PMID 12559038·Breast Cancer Res·2003
6-review
Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis.
PMID 12023956·J Biol Chem·2002
8-other
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
PMID 12431963·J Clin Oncol·2002
3-trial
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
PMID 19494840·Leukemia·2009
6-review
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma.
PMID 19436606·Ther Clin Risk Manag·2009
8-other
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
PMID 19344406·Br J Haematol·2009
4-observational
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
PMID 19050304·Blood·2009
8-other
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
PMID 18300257·Cancer·2008
3-trial
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
PMID 18305219·Blood·2008
8-other
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
PMID 18327587·Cancer Chemother Pharmacol·2008
3-trial
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
PMID 18765533·Clin Cancer Res·2008
8-other
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
PMID 19064400·Clin Lymphoma Myeloma·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3400 SPRUCE ST
PHILADELPHIA, PA 19104 - Phone
- (215) 662-2200
Quick Facts
- NPI
- 1417276379
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile